Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 9, 2009, Pages 1505-1509

  Tanaka, Hiroyuki ^a   Saito, Katsuhiko ^a,b   Mino, Kozo ^c   Izumi, Keishiro ^a   Harada, Masao ^a   Isobe, Hiroshi ^d  

^a HOKKAIDO CANCER CENTER   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d KKR Sapporo Medical Center   (Japan)

Author keywords

AUC; Bilirubin; Irinotecan; SN 38; SN 38G

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENETICS;

EID: 79959815649     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005. (Pubitemid 40175974)
2. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002.
3. Rivory LP and Robert J: Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36(2): 176-179, 1995.
4. Strassburg CP: Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9(6): 703-715, 2008.
5. Nies AT and Keppler D: The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453(5): 643-659, 2007. (Pubitemid 46192536)
6. Ramchandani RP, Wang Y, Booth BP, et al: The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47(1): 78-86, 2007. (Pubitemid 44974001)
7. Sai K, Saeki M, Saito Y, et al: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75(6): 501-515, 2004. (Pubitemid 38746601)
8. Wasserman E, Myara A, Lokiec F, et al: Severe CPT-11 toxicity in patients with Gilbert's syndrome. Ann Oncol 8(10): 1049-1051, 1997. (Pubitemid 27475739)
9. Lankisch TO, Schulz C, Zwingers T, et al: Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants icrease risk. Cancer Epidemiol Biomarkers Prev 17(3): 695-701, 2008. (Pubitemid 351469222)
10. Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 *6 and *28. Pharmacogenet Genomics 17(7): 497-504, 2007.
11. Mahalati K, Belitsky P, Sketris I, et al: Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68(1): 55-62, 1999. (Pubitemid 29352830)
12. Kurita A and Kaneda N: High-performance liquid chromatographic method for the simultaneous determination of the camptotecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solidphase extraction system, PROSPEKT. J Chromatogr B Biomed Sci Appl 724(2): 335-344, 1999. (Pubitemid 29148095)
13. Araki K, Fujita K, Ando Y, et al: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97(11): 1255-1259, 2006. (Pubitemid 44430653)
14. Zhou Q, Sparreboom A, Tan EH, et al: Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59(4): 415-424, 2005. (Pubitemid 40523885)
15. Ando Y, Saka H, Asai G, et al: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. A nn Oncol 9(8): 845-847, 1998.
16. Ando Y, Ueoka H, Sugiyama T, et al: Polymorphisms of UDP- glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24(1): 111-116, 2002.